目次

1. China Bispecific Antibodies Market Overview

2. Bispecific Antibodies Available For Licensing In China

3. China Bispecific Antibodies Clinical Trials Landscape
3.1 By Company
3.2 By Indication
3.3 By Patient Segment
3.4 By Phase

4. China Bispecific Antibodies Clinical Pipeline By Company, Indication and Phase
4.1 Research
4.2 Preclinical
4.3 Phase-I
4.4 Phase-I/II
4.5 Phase-II
4.6 Phase-III
4.7 Preregistration
4.8 Registered

5. China - Marketed Bispecific Antibodies Clinical Insight

6. China Bispecific Antibodies Market Dynamics
6.1 Favorable Market Parameters
6.2 Market Challenges and Restraints

7. China Bispecific Antibodies Market Opportunity Outlook

8. China Pharmaceutical Sector Regulatory Affairs and Policies Outline
8.1 Approval and Regulatory Bodies
8.2 Government Policy Framework

9. Provisions for Drug Registration: Order of the State Administration for Market Regulation

10. Competitive Landscape
10.1 Akeso Biopharma
10.2 Alphamab Oncology
10.3 Beijing Biocytogen
10.4 BeiGene
10.5 Biotheus
10.6 BJ Bioscience
10.7 EpimAb Biotherapeutics
10.8 I-MAB Biopharma
10.9 Innovent Biologics
10.10 Linton Pharm
10.11 Lyvgen Biopharma
10.12 WuXi Biologics

List of Figures & Tables
Figure 1-1: China - Bispecific Antibodies Market Estimate (US$ Million), 2022 - 2028
?
Figure 3-1: China - Bispecific Antibodies In Clinical Pipeline By Company (Numbers), 2022 Till 2028
Figure 3-2: China - Bispecific Antibodies In Clinical Pipeline By Indication (Numbers), 2022 Till 2028
Figure 3-3: China - Bispecific Antibodies In Clinical Pipeline By Patient Segment (Numbers), 2022 Till 2028
Figure 3-4: China - Bispecific Antibodies Clinical Pipeline By Phase (Numbers), 2022 till 2028
Figure 7-1: China - Health Expenditure (US$/Yuan Billion), 2016-2020
Figure 8-1: China - Drug Regulatory Framework
Figure 8-2: NMPA - Affiliated Organizations